NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.11
Percentage change 2.99	%

Peers: MDGL VKTX AKRO MNOV LGND GLMD BCRX XBIT ACAD AMRN

| Held by: VTI IWM VXF IWN IBB VTWO OZEM DFAS DFAT IWC

Index	RUT	P/E	-	EPS (ttm)	-1.09	Insider Own	23.95%	Shs Outstand	87.30M	Perf Week	-5.49%
Market Cap	331.01M	Forward P/E	-	EPS next Y	-1.21	Insider Trans	-0.09%	Shs Float	66.42M	Perf Month	28.91%
Enterprise Value	-2.01M	PEG	-	EPS next Q	-0.29	Inst Own	77.30%	Short Float	8.19%	Perf Quarter	7.98%
Income	-90.39M	P/S	-	EPS this Y	-6.16%	Inst Trans	-2.67%	Short Ratio	5.39	Perf Half Y	-34.20%
Sales	0.00M	P/B	1.01	EPS next Y	-2.17%	ROA	-30.84%	Short Interest	5.44M	Perf YTD	-31.59%
Book/sh	3.73	P/C	0.99	EPS next 5Y	-7.00%	ROE	-32.12%	52W High	11.40 -66.75%	Perf Year	-45.70%
Cash/sh	3.83	P/FCF	-	EPS past 3/5Y	17.43% 16.38%	ROIC	-27.65%	52W Low	1.87 103.22%	Perf 3Y	108.24%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.21% 3.58%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	13.56%	Oper. Margin	-	ATR (14)	0.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	30.89	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	57.47	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	30.89	EPS Q/Q	13.07%	SMA20	4.17%	Beta	-0.18	Target Price	19.14
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	18.42%	Rel Volume	0.67	Prev Close	3.68
Employees	59	LT Debt/Eq	0.00	Earnings	May 08 AMC	SMA200	-26.03%	Avg Volume	1.01M	Price	3.79
IPO	Feb 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.53% -	Trades		Volume	670,794	Change	2.99%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Oct-31-24	Initiated	Oppenheimer	Outperform	$82
Jun-22-23	Initiated	Mizuho	Buy	$16
Jun-07-23	Initiated	Jefferies	Buy	$18
May-31-23	Initiated	ROTH MKM	Buy	$23
May-08-23	Initiated	BMO Capital Markets	Outperform	$18
Feb-14-23	Initiated	JMP Securities	Mkt Outperform	$17
Feb-07-23	Initiated	UBS	Buy	$19
Sep-12-22	Initiated	H.C. Wainwright	Neutral	$6
Sep-14-21	Resumed	Goldman	Buy	$21
Mar-02-21	Initiated	JP Morgan	Overweight	$32
Mar-02-21	Initiated	Goldman	Buy	$29
Mar-02-21	Initiated	Cowen	Outperform

Show Previous Ratings

Jun-23-25 04:07PM	Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions (GlobeNewswire) -5.64%
May-29-25 04:05PM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 (GlobeNewswire)
May-09-25 07:54AM	Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 04:05PM	Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
04:05PM	Loading…
May-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -5.71%
Apr-30-25 04:05PM	Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference (GlobeNewswire) +6.11% +7.88%
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-07-25 09:35AM	Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround (Zacks)
Apr-03-25 09:35AM	Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN) (Zacks) -6.43%
Apr-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Mar-26-25 12:00PM	All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy (Zacks) -6.63%
Mar-20-25 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire) +6.69%
Mar-09-25 10:03AM	This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street (Motley Fool)
Feb-26-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
08:05AM	Loading…
Feb-25-25 08:05AM	Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference (GlobeNewswire)
03:00AM	Its CEO died. The company scrapped a promising program. Now, for their 2nd act. (Pharma Voice)
Feb-24-25 04:05PM	Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer (GlobeNewswire) -6.87%
Feb-20-25 04:05PM	Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors (GlobeNewswire)
Feb-05-25 04:05PM	Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-03-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-08-25 04:05PM	Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.84%
Jan-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-16-24 01:10PM	Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia (GlobeNewswire)
Dec-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-18-24 04:05PM	Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors (GlobeNewswire) -7.62%
Nov-12-24 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire) -5.44%
Nov-06-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -5.08%
03:22AM	Loading…
Sep-24-24 03:22AM	Insiders Snap Up These 2 Strong Buy Stocks (TipRanks)
Sep-18-24 10:07AM	This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments (Motley Fool) +6.02%
Sep-17-24 01:30AM	OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc (GuruFocus.com)
Sep-15-24 07:21AM	Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. (Motley Fool)
06:09AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Sep-14-24 10:12AM	1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More (Motley Fool)
Sep-12-24 07:00PM	Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.96% -5.84%
Sep-10-24 10:50PM	Terns Announces Pricing of Upsized $150.15 Million Public Offering (GlobeNewswire) +23.14%
04:52AM	Terns Pharmaceuticals reports positive data from Phase I trial of obesity treatment (Clinical Trials Arena)
Sep-09-24 04:01PM	Terns Announces Proposed Public Offering (GlobeNewswire) +16.77%
09:58AM	Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill (Barrons.com)
09:24AM	Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month (Benzinga)
08:06AM	Early study data puts Terns among obesity drug contenders (BioPharma Dive)
07:05AM	Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity (GlobeNewswire)
Aug-28-24 09:55AM	Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet (Zacks)
Aug-05-24 09:56PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Aug-02-24 01:54PM	3 Biotech Stocks That Could Have Investors Grinning Soon (InvestorPlace)
Aug-01-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-29-24 04:05PM	Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition (GlobeNewswire) -7.55% -7.92%
Jul-26-24 06:40PM	Burger King Parent Company and More Stocks See Action From Activist Investors (Barrons.com)
Jul-20-24 09:30AM	Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? (Motley Fool)
Jun-21-24 06:30PM	Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation (GlobeNewswire)
Jun-19-24 01:27PM	Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue? (Zacks)
Jun-04-24 09:55AM	Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade (Zacks)
Jun-03-24 04:10PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
May-30-24 08:05AM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-17-24 04:05PM	Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day (GlobeNewswire) +5.93%
May-13-24 01:53PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024 (InvestorPlace) +5.94%
09:32AM	Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections (GuruFocus.com)
08:05AM	Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-08-24 04:05PM	Terns Pharmaceuticals Announces Leadership Changes (GlobeNewswire) +5.03%
May-07-24 04:05PM	Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024 (GlobeNewswire)
May-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.43%
Apr-29-24 04:05PM	Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation (GlobeNewswire)
Apr-10-24 04:05PM	Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer (GlobeNewswire) -5.23%
Mar-14-24 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire) -5.23% +7.30%
Mar-11-24 04:05PM	Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire) -8.38%
Mar-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Feb-27-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences (GlobeNewswire) +5.69% -6.26%
Feb-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.13% +9.81%
08:05AM	Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer (GlobeNewswire)
Feb-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-04-24 04:05PM	Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.52%
Jan-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-29-23 04:05PM	Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit (GlobeNewswire) +6.97%
Nov-27-23 04:05PM	Terns Pharmaceuticals Mourns the Loss of Senthil Sundaram, Former Chief Executive Officer (GlobeNewswire) +5.96%
Nov-14-23 12:16PM	Terns Pharmaceuticals Inc (TERN) Reports Q3 2023 Financials and Corporate Progress (GuruFocus.com) +5.34%
08:05AM	Terns Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire)
Nov-13-23 08:05AM	Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH at AASLD The Liver Meeting 2023 (GlobeNewswire)
Nov-09-23 08:05AM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire) -21.89%
Nov-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-02-23 04:05PM	Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity (GlobeNewswire) -8.00%
Oct-19-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.61%
Oct-16-23 08:05AM	Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia (GlobeNewswire)
Oct-03-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-06-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-05-23 04:05PM	Terns Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-08-23 04:15PM	Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates (GlobeNewswire) -13.73%
04:05PM	Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR- Agonist TERN-501 in NASH (GlobeNewswire)
Aug-03-23 06:00PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -6.80%
05:05PM	Terns Pharmaceuticals Announces Leadership Transition (GlobeNewswire)
Jul-28-23 07:01PM	Deep Track Capital, LP Enters Position in Terns Pharmaceuticals Inc (GuruFocus.com)
Jul-18-23 04:05PM	Terns Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss TERN-701 and Advances in the Treatment Landscape for Chronic Myeloid Leukemia (GlobeNewswire) +5.17%
Jul-05-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jun-26-23 04:05PM	Terns Pharmaceuticals Highlights New Preclinical Data for TERN-601 Program in Obesity at the ADAs 83rd Annual Scientific Session and Upcoming Events (GlobeNewswire) -12.16% -23.52%
Jun-06-23 04:30PM	Terns Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
Jun-02-23 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.17%
May-28-23 09:45AM	Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth (Simply Wall St.)
May-25-23 05:05PM	Terns Pharmaceuticals Announces Publication of TERN-701 Trial-in-Progress Abstract for the 2023 ASCO Annual Meeting (GlobeNewswire)

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gengos Andrew	Chief Financial Officer	Jun 13 '25	Buy	3.73	10,000	37,350	10,000	Jun 16 06:05 PM
Gengos Andrew	Chief Financial Officer	Jun 16 '25	Buy	3.95	5,000	19,732	15,000	Jun 16 06:05 PM
Kuriakose Emil	Chief Medical Officer	Apr 01 '25	Sale	2.49	952	2,366	53,317	Apr 02 06:48 PM
Jung Melita Sun	Chief Business Officer	Nov 30 '24	Buy	5.11	2,250	11,498	2,250	Feb 03 07:28 PM
Burroughs Amy L.	Chief Executive Officer	Nov 30 '24	Buy	5.11	510	2,606	19,609	Feb 03 07:25 PM
Kuriakose Emil	Chief Medical Officer	Jan 02 '25	Sale	5.71	4,481	25,607	54,269	Jan 06 07:30 PM
Vignola Mark J.	Chief Financial Officer	Jan 06 '25	Sale	5.80	9,059	52,500	74,752	Jan 06 07:30 PM
Vignola Mark J.	Chief Financial Officer	Jan 02 '25	Sale	5.72	8,129	46,524	83,811	Jan 06 07:30 PM
Quigley Jill M.	Director	Jan 06 '25	Sale	5.79	8,760	50,758	0	Jan 06 07:30 PM
Quigley Jill M.	Director	Jan 02 '25	Sale	5.72	6,240	35,702	8,760	Jan 06 07:30 PM
MARK J VIGNOLA	Officer	Jan 06 '25	Proposed Sale	5.75	9,059	52,089		Jan 06 04:29 PM
JILL QUIGLEY	Director	Jan 06 '25	Proposed Sale	5.75	8,760	50,370		Jan 06 04:29 PM
Burroughs Amy L.	Chief Executive Officer	Dec 05 '24	Buy	7.15	15,450	110,468	19,099	Dec 09 06:04 PM
Lu Hongbo	Director	Sep 12 '24	Buy	10.50	476,190	4,999,995	476,190	Sep 17 07:48 PM
Vignola Mark J.	Chief Financial Officer	Sep 10 '24	Option Exercise	5.36	10,000	53,600	101,940	Sep 12 06:10 PM
Vignola Mark J.	Chief Financial Officer	Sep 10 '24	Sale	11.00	10,000	110,000	91,940	Sep 12 06:10 PM
Quigley Jill M.	Director	Sep 09 '24	Option Exercise	1.82	17,235	31,368	32,235	Sep 11 06:00 PM
Quigley Jill M.	Director	Sep 09 '24	Sale	10.00	17,235	172,350	15,000	Sep 11 06:00 PM
SEOKHO BRYAN YOON	Officer	Sep 10 '24	Proposed Sale	9.12	10,000	91,200		Sep 10 04:21 PM
MARK J VIGNOLA	Officer	Sep 10 '24	Proposed Sale	9.12	10,000	91,200		Sep 10 04:21 PM
JILL QUIGLEY	Officer	Sep 09 '24	Proposed Sale	7.81	8,857	69,173		Sep 09 04:30 PM
Quigley Jill M.	Director	Aug 02 '24	Sale	7.50	8,857	66,432	15,000	Aug 05 08:11 PM
Quigley Jill M.	Director	Aug 01 '24	Sale	7.68	6,143	47,148	23,857	Aug 05 08:11 PM
GORDON CARL L	Director	Jul 15 '24	Sale	10.00	50,976	509,760	756,258	Jul 17 08:53 PM
GORDON CARL L	Director	Jul 16 '24	Sale	10.00	5,188	51,880	755,635	Jul 17 08:53 PM
ORBIMED ADVISORS LLC	Director	Jul 15 '24	Sale	10.00	50,976	509,760	756,258	Jul 17 08:48 PM
ORBIMED ADVISORS LLC	Director	Jul 16 '24	Sale	10.00	5,188	51,880	755,635	Jul 17 08:48 PM
Quigley Jill M.	Director	Jul 15 '24	Option Exercise	1.82	14,365	26,144	44,365	Jul 17 07:56 PM
Quigley Jill M.	Director	Jul 16 '24	Option Exercise	1.82	400	728	30,400	Jul 17 07:56 PM
Quigley Jill M.	Director	Jul 15 '24	Sale	10.00	14,365	143,660	30,000	Jul 17 07:56 PM
Quigley Jill M.	Director	Jul 16 '24	Sale	10.00	400	4,000	30,000	Jul 17 07:56 PM

Open in Screener

ATHA

Athira Pharma Inc

Jun 24 • 04:00PM ET

0.2980

Dollar change +0.0020
Percentage change 0.68	%

Healthcare • Biotechnology • USA • NASD

ATHA Athira Pharma Inc daily Stock Chart

Peers: BIIB SAVA AVXL SAGE QURE PRTA INVA AUPH NBIX ANVS

| Held by: SURI VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-2.07	Insider Own	13.71%	Shs Outstand	39.04M	Perf Week	-6.99%
Market Cap	11.64M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	-1.03%	Shs Float	33.69M	Perf Month	10.17%
Enterprise Value	-23.91M	PEG	-	EPS next Q	-0.18	Inst Own	45.08%	Short Float	2.66%	Perf Quarter	-12.35%
Income	-79.75M	P/S	-	EPS this Y	75.66%	Inst Trans	14.32%	Short Ratio	1.61	Perf Half Y	-45.17%
Sales	0.00M	P/B	0.31	EPS next Y	29.35%	ROA	-90.12%	Short Interest	0.89M	Perf YTD	-49.21%
Book/sh	0.96	P/C	0.32	EPS next 5Y	62.77%	ROE	-110.70%	52W High	3.67 -91.88%	Perf Year	-86.99%
Cash/sh	0.94	P/FCF	-	EPS past 3/5Y	-19.25% -73.94%	ROIC	-209.74%	52W Low	0.22 35.73%	Perf 3Y	-96.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	1.87% 5.42%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	32.23%	Oper. Margin	-	ATR (14)	0.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.26	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.06	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.26	EPS Q/Q	65.92%	SMA20	-4.61%	Beta	3.03	Target Price	0.40
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	4.07%	Rel Volume	0.12	Prev Close	0.30
Employees	26	LT Debt/Eq	0.02	Earnings	May 09 AMC	SMA200	-31.96%	Avg Volume	556.42K	Price	0.30
IPO	Sep 18, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.17% -	Trades		Volume	68,237	Change	0.68%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral	$5 → $0.50
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy	$22
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$20
Jul-07-22	Initiated	Mizuho	Buy	$6
Jun-23-22	Downgrade	Stifel	Buy → Hold	$36 → $5
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold	$32 → $3
May-10-22	Initiated	BTIG Research	Buy	$33
Apr-21-22	Initiated	Berenberg	Buy	$33
Dec-15-21	Initiated	Goldman	Neutral	$16
Oct-13-20	Initiated	Stifel	Buy	$36
Oct-13-20	Initiated	JMP Securities	Mkt Outperform	$51
Oct-13-20	Initiated	Jefferies	Buy	$30
Oct-13-20	Initiated	Goldman	Buy	$53

Show Previous Ratings

May-14-25 11:10AM	Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105 (TipRanks) -7.25%
May-13-25 11:00AM	Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit (GlobeNewswire)
May-09-25 04:05PM	Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.17%
Feb-27-25 04:05PM	Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Dec-06-24 05:30PM	Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND (GlobeNewswire)
04:50AM	Loading…
Nov-08-24 04:50AM	Athira exploring strategic alternatives after Alzheimers failure (BioPharma Dive) -12.01%
Nov-07-24 04:05PM	Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire) +7.14%
Oct-22-24 07:00AM	Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting (GlobeNewswire) +15.73%
Sep-17-24 09:00AM	Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases (GlobeNewswire)
Sep-04-24 11:40AM	Alzheimers Trial Failure Sends Athira Stock Down 75% (Barrons.com) -78.43%
11:33AM	Athiras stock topples after Alzheimers drug flops in Phase II/III trial (Pharmaceutical Technology)
08:48AM	Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks (Benzinga)
Sep-03-24 04:01PM	Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) -8.41%
Aug-23-24 09:40AM	Are Medical Stocks Lagging Athira Pharma (ATHA) This Year? (Zacks) +6.75%
Aug-07-24 09:40AM	Is Athira Pharma (ATHA) Stock Outpacing Its Medical Peers This Year? (Zacks)
04:05PM	Loading…
Aug-01-24 04:05PM	Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
Jul-31-24 08:05AM	Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024 (GlobeNewswire)
Jul-10-24 08:51AM	Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up (Zacks)
Jul-09-24 07:00AM	Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire) +29.39%
Jun-12-24 07:00AM	Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients (GlobeNewswire)
Jun-11-24 07:00AM	Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
May-29-24 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-17-24 05:00PM	Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action (GlobeNewswire) -7.01%
May-15-24 10:54PM	ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024 (InvestorPlace) +22.62%
04:05PM	Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates (GlobeNewswire)
May-07-24 09:15AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE) +10.66%
May-02-24 07:00AM	Athira Pharma to Participate in Upcoming May Conferences (GlobeNewswire)
Apr-15-24 07:00AM	Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer (GlobeNewswire) -15.57%
Apr-11-24 07:00AM	Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease (GlobeNewswire) +6.85%
Apr-03-24 07:00AM	Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
07:00AM	Loading…
Mar-08-24 07:00AM	Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer's and Parkinson's Diseases at AD/PD 2024 International Conference (GlobeNewswire) -13.73%
Feb-28-24 12:00PM	Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy? (Zacks)
Feb-22-24 04:05PM	Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +6.22%
Feb-15-24 02:56PM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +12.27%
Feb-08-24 04:02PM	Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire)
Jan-08-24 07:00AM	Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update (GlobeNewswire) +10.45%
Jan-03-24 07:00AM	Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease (GlobeNewswire)
Dec-12-23 07:00AM	Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies (GlobeNewswire)
Dec-05-23 10:25AM	Sidoti Events, LLC's Virtual December Small-Cap Conference (ACCESSWIRE)
Nov-29-23 07:00AM	Athira Pharma to Participate in Sidoti December Small Cap Investor Conference (GlobeNewswire)
Nov-28-23 07:00AM	Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association's 34 International Symposium on ALS/MND (GlobeNewswire) -5.88%
Nov-15-23 08:15AM	Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid- -Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease (GlobeNewswire)
Nov-09-23 04:05PM	Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) -7.33% +6.47%
Nov-08-23 07:00AM	Athira Pharma to Participate in Jefferies London Healthcare Conference (GlobeNewswire)
Oct-05-23 04:30PM	Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS) (GlobeNewswire) +5.00%
Sep-28-23 07:00AM	Athira Pharma to Participate in Upcoming October Conferences (GlobeNewswire) +5.26%
Sep-19-23 07:00AM	Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-08-23 12:00PM	All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy (Zacks)
Aug-31-23 09:35AM	Down -24.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Athira Pharma, Inc. (ATHA) (Zacks)
Aug-29-23 09:55AM	Athira Pharma, Inc. (ATHA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-10-23 04:05PM	Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates (GlobeNewswire) +5.21% -7.26%
Jul-17-23 07:00AM	Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimers Disease (GlobeNewswire)
Jul-06-23 11:52AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
07:00AM	Athira Pharma Announces Upcoming Presentations at the Alzheimers Association International Conference (AAIC) 2023 (GlobeNewswire)
Jun-08-23 06:08AM	Andrew Gengos Spends US$192k On Athira Pharma Stock \ (Simply Wall St.)
Jun-07-23 08:10AM	Daily Vickers Top Buyers & Sellers for 06/07/2023 (Argus Research) +12.54%
May-31-23 07:00AM	Athira Pharma to Participate in Upcoming June Conferences (GlobeNewswire)
May-22-23 07:00AM	Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
May-12-23 11:34AM	FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing (Zacks)
May-11-23 04:05PM	Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
12:25PM	Jazz (JAZZ) Lags on Q1 Earnings & Sales, Reaffirms '23 View (Zacks)
May-08-23 07:00AM	Athira Pharma to Participate in Upcoming May Investor Conferences (GlobeNewswire)
Apr-29-23 08:45AM	Athira Pharma, Inc. (NASDAQ:ATHA) is a favorite amongst institutional investors who own 58% (Simply Wall St.)
Apr-25-23 04:01PM	Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-11-23 07:00AM	Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting (GlobeNewswire)
Apr-02-23 08:14AM	Trade Alert: The Independent Director Of Athira Pharma, Inc. (NASDAQ:ATHA), Grant Pickering, Has Just Spent US$60k Buying 3,193% More Shares (Simply Wall St.)
Mar-28-23 12:00PM	Athira Pharma, Inc. (ATHA) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
01:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimers and Parkinsons Diseases at AD/PD 2023 International Conference (GlobeNewswire)
Mar-23-23 04:05PM	Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates (GlobeNewswire)
Mar-08-23 07:00AM	Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences (GlobeNewswire)
Mar-06-23 07:00AM	Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences (GlobeNewswire)
Feb-01-23 07:00AM	Athira Pharma Announces Publication in Journal of Alzheimers Disease Highlighting Need for Novel Alzheimers Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway (GlobeNewswire)
Jan-31-23 07:00AM	Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer (GlobeNewswire)
Jan-28-23 08:00AM	How Athira and its former CEO are moving on after controversial split (American City Business Journals)
Jan-27-23 10:08AM	Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-17-23 01:00AM	Former Athira CEO on her controversial exit: 'I was relieved that it came to an end' (American City Business Journals)
Jan-05-23 07:00AM	Athira Pharma Provides 2023 Pipeline Outlook (GlobeNewswire)
Jan-03-23 06:26AM	Daily Vickers Top Buyers & Sellers for 01/03/2023 (Argus Research) +6.62%
Dec-21-22 07:00AM	Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics (GlobeNewswire)
Dec-09-22 05:34AM	Insider Buying: The Athira Pharma, Inc. (NASDAQ:ATHA) Independent Chairwoman of the Board Just Bought 361% More Shares (Simply Wall St.)
Dec-05-22 07:30AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -10.37%
Dec-01-22 07:00AM	Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 3:30 pm Eastern time (GlobeNewswire)
Nov-29-22 11:00AM	Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimers Disease Patients from ACT-AD Phase 2 Study at CTAD Conference (GlobeNewswire)
Nov-28-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND (GlobeNewswire) -5.02%
Nov-21-22 07:00AM	Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimers Disease (CTAD) Conference (GlobeNewswire)
Nov-16-22 07:00AM	Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference (GlobeNewswire)
Nov-10-22 04:05PM	Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire) +7.97% +8.39%
Nov-09-22 07:00AM	Athira Pharma to Present at Stifel 2022 Healthcare Conference (GlobeNewswire) -7.07%
Nov-07-22 07:00AM	Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference (GlobeNewswire)
Oct-30-22 08:29AM	Athira Pharma, Inc. (NASDAQ:ATHA) has caught the attention of institutional investors who hold a sizeable 47% stake (Simply Wall St.)
Oct-17-22 07:00AM	Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients Following Independent, Unblinded Interim Analysis (GlobeNewswire) +9.03%
Sep-16-22 08:14AM	Multiple insiders bought Athira Pharma, Inc. (NASDAQ:ATHA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-06-22 03:22PM	Athira Outlines Possible Comeback For Alzheimer's Candidate (Benzinga)
07:00AM	Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients (GlobeNewswire)
Aug-20-22 08:01AM	Athira Pharma (NASDAQ:ATHA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Aug-15-22 04:05PM	Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates (GlobeNewswire)
Aug-03-22 11:28AM	Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimers Patients at the Alzheimer's Association International Conference 2022 (GlobeNewswire)
Aug-02-22 03:30PM	Athira Pharma Presents Preclinical Data at the Alzheimer's Association International Conference 2022 (GlobeNewswire)
Jul-25-22 07:00AM	Athira Pharma to Present Clinical and Preclinical Data at Alzheimers Association International Conference 2022 (GlobeNewswire)
Jul-08-22 04:19PM	Rapid Micro and Athira Pharma Stock See Action From Activist Investors (Barrons.com) -11.44%

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
San Martin Javier	CHIEF MEDICAL OFFICER	Dec 31 '24	Option Exercise	0.00	46,667	0	46,667	Jan 03 05:05 PM
San Martin Javier	CHIEF MEDICAL OFFICER	Jan 02 '25	Sale	0.56	10,826	6,083	35,841	Jan 03 05:05 PM
Litton Mark James	President and CEO	Dec 31 '24	Option Exercise	0.00	108,333	0	267,698	Jan 03 05:04 PM
Litton Mark James	President and CEO	Jan 02 '25	Sale	0.56	25,107	14,108	242,591	Jan 03 05:04 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Dec 31 '24	Option Exercise	0.00	36,667	0	139,271	Jan 03 05:03 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Jan 02 '25	Sale	0.56	8,510	4,782	130,761	Jan 03 05:03 PM
Renninger Robert	VP of Finance	Dec 31 '24	Option Exercise	0.00	12,359	0	92,605	Jan 03 05:01 PM
Renninger Robert	VP of Finance	Jan 02 '25	Sale	0.56	2,881	1,619	89,724	Jan 03 05:01 PM
Worthington Mark	General Counsel and CCO	Dec 31 '24	Option Exercise	0.00	36,667	0	92,245	Jan 03 05:00 PM
Worthington Mark	General Counsel and CCO	Jan 02 '25	Sale	0.56	8,510	4,782	83,735	Jan 03 05:00 PM
Javier San Martin	Officer	Jan 02 '25	Proposed Sale	0.56	10,826	6,083		Jan 02 08:06 PM
Mark James Litton	Officer	Jan 02 '25	Proposed Sale	0.56	25,107	14,108		Jan 02 08:05 PM
Mark Worthington	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:04 PM
Kevin Church	Officer	Jan 02 '25	Proposed Sale	0.56	8,510	4,782		Jan 02 08:02 PM
Mark James Litton	Officer	Sep 05 '24	Proposed Sale	0.00	5,032	1		Sep 05 07:53 PM
Gengos Andrew	CFO and Chief Business Officer	Sep 05 '24	Sale	0.57	1,272	720	97,532	Sep 05 07:51 PM
Lenington Rachel	COO and CDO	Sep 05 '24	Sale	0.57	2,525	1,429	20,870	Sep 05 07:50 PM
CHURCH KEVIN	CHIEF SCIENTIFIC OFFICER	Sep 05 '24	Sale	0.57	2,525	1,429	92,684	Sep 05 07:49 PM
Worthington Mark	GENERAL COUNSEL	Sep 05 '24	Sale	0.57	2,525	1,429	51,927	Sep 05 07:48 PM
Litton Mark James	President and CEO	Sep 05 '24	Sale	0.57	5,032	2,848	159,365	Sep 05 07:47 PM

TERN

Terns Pharmaceuticals Inc

ATHA

Athira Pharma Inc

Upgrade your FINVIZ experience